No Picture
News

Qualigen Therapeutics Completes Recertification of Existing AS1411 Drug Supply for Use in Upcoming Clinical Trials

CARLSBAD, Calif., Dec. 2, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces that it has completed the recertification of its supply of AS1411, and has begun final formulation and filling for use in the Company’s proposed Phas… […]

No Picture
News

Persephone Biosciences Initiates the ARGONAUT Study of Gut Microbiome-Linked Immune Modulation in Cancer Treatment Response

– Company aims to apply machine learning to large datasets created by this study to identify approaches to increase patient response to existing oncology treatments as well as identify new therapeutic targets — Planned enrollment of 4,000 patients mak… […]

No Picture
News

Study Shows Biocept’s Assays are Viable and Sensitive for Detecting Tumor Cells and Biomarkers in the Cerebrospinal Fluid of Patients with Breast and Lung Cancer that has Metastasized to the Central Nervous System

SAN DIEGO, Nov. 20, 2020 /PRNewswire/ — Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outco… […]

No Picture
News

Kintara Therapeutics Reports 10 Months Progression-Free Survival in Newly-Diagnosed MGMT-unmethylated GBM from Ongoing MD Anderson Cancer Center Phase 2 Study

Positive Data Updates Presented at the Society of Neuro-Oncology (SNO) Annual Meeting in Newly-Diagnosed, Recurrent, and First-Line GBM- In the Newly-Diagnosed Treatment Setting, Promising Median Progression-Free Survival of 10.0 months with VAL-083 Co… […]

No Picture
News

Promising new data for Ionis’ antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020

– Single doses resulted in potent, dose-dependent PCSK9 reductions of up to >90%, demonstrating best-in-class potential for the treatment of patients with high cholesterol at risk of cardiovascular disease

CARLSBAD, Calif., Nov. 13, 2020 /PRNewswire/… […]

No Picture
News

Halozyme Announces Janssen Submission Of Applications In US And EU Seeking Approval Of DARZALEX FASPRO(TM)/ DARZALEX® Subcutaneous (SC) Formulation Utilizing ENHANZE® Technology, Combination With Pomalidomide And Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma

SAN DIEGO, Nov. 12, 2020 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the Janssen Pharmaceutical Companies submitted regulatory applications to the U.S. Food and Drug Administration (FDA) and European Medicines Age… […]

No Picture
News

Denovo Biopharma LLC’s Phase 3 Pivotal ENGINE Study of DB102 (Enzastaurin) in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Is Fully Enrolled

SAN DIEGO, Nov. 12, 2020 /PRNewswire/ — Denovo Biopharma, a pioneer in applying precision medicine to development of innovative therapies, today announced that its international Phase 3 registrational study for DB102 has fully enrolled. The ENGINE … […]

No Picture
News

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

– Disease control observed in 92% of patients- Conference call to be held today at 2:30pm PT

SAN DIEGO, Nov. 11, 2020 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced updated … […]